Taiwanese vaccine manufacturer Adimmune Corp (國光生技) yesterday signed a cooperation pact with China-based Shenzhen Techdow Pharmaceutical Co Ltd (天道醫藥) to produce enoxaparin sodium injections, which are used to prevent and treat blood clots.
The cooperation would unite Adimmune’s aseptic ampoule-filling technology with Techdow Pharmaceutical’s enoxaparin sodium manufacturing technology, allowing the firms to produce injections that can pass the high standards set in Europe and the US.
The patent for the original blood clot prevention drug has expired, but it would be difficult to develop a new drug that is as effective, Techdow Pharmaceutical general manager Jake Li (李建科) said yesterday.
Each year, 100 million units of enoxaparin sodium injections are sold in the US market and 360 million in Europe. Sales are estimated to be about US$2 billion per year in both regions, Li said.
Adimmune will manufacture the product in local factories starting next year and is expected to be certified by the European Medicines Agency as a manufacturer of the injections by next year, chief financial officer Vic Chang (張哲瑋) said.
The two companies plan to manufacture 10 million units a year at first, and increase production volume to 50 million units within three to five years, he said.
Adimmune reported consolidated losses of NT$603.68 million (US$20.24 million) last year, 28 percent more than the NT$471.32 million loss it posted a year ago, which the company attributed to lower profit margins for flu vaccines.
The Greater Taichung-based company expects a better outlook for this year once another of its partnerts, Dutch biotech firm Crucell NV, receives more approvals to distribute Adimmune’s flu vaccines in Europe.
The company’s flu vaccines were approved for sale in Germany, the UK and Italy last year, and received the green light in Switzerland last month. The vaccines are currently being reviewed by other European countries, as well as the Pan-American Health Organization, Adimmune said.
“We are striving to swing to the black this year,” Chang said.
Adimmune chairman Steve Chan (詹啟賢) said the company is capable of producing between 5 million and 10 million units of a preliminary vaccine for H7N9 — a subtype of the avian influenza virus — within two months if the strain spreads beyond control, citing its extensive experience producing the vaccine for avian flu subtype H1N1.
Preliminary vaccines are used when a vaccine cannot be developed or manufactured in time to stop a sudden outbreak, Chan said, adding that there is currently no specific vaccine for H7N9.
Adimmune’s shares rose 6.97 percent to NT$40.65 yesterday, outperforming the TAIEX, which was up 0.18 percent.
ISSUES: Gogoro has been struggling with ballooning losses and was recently embroiled in alleged subsidy fraud, using Chinese-made components instead of locally made parts Gogoro Inc (睿能創意), the nation’s biggest electric scooter maker, yesterday said that its chairman and CEO Horace Luke (陸學森) has resigned amid chronic losses and probes into the company’s alleged involvement in subsidy fraud. The board of directors nominated Reuntex Group (潤泰集團) general counsel Tamon Tseng (曾夢達) as the company’s new chairman, Gogoro said in a statement. Ruentex is Gogoro’s biggest stakeholder. Gogoro Taiwan general manager Henry Chiang (姜家煒) is to serve as acting CEO during the interim period, the statement said. Luke’s departure came as a bombshell yesterday. As a company founder, he has played a key role in pushing for the
China has claimed a breakthrough in developing homegrown chipmaking equipment, an important step in overcoming US sanctions designed to thwart Beijing’s semiconductor goals. State-linked organizations are advised to use a new laser-based immersion lithography machine with a resolution of 65 nanometers or better, the Chinese Ministry of Industry and Information Technology (MIIT) said in an announcement this month. Although the note does not specify the supplier, the spec marks a significant step up from the previous most advanced indigenous equipment — developed by Shanghai Micro Electronics Equipment Group Co (SMEE, 上海微電子) — which stood at about 90 nanometers. MIIT’s claimed advances last
EUROPE ON HOLD: Among a flurry of announcements, Intel said it would postpone new factories in Germany and Poland, but remains committed to its US expansion Intel Corp chief executive officer Pat Gelsinger has landed Amazon.com Inc’s Amazon Web Services (AWS) as a customer for the company’s manufacturing business, potentially bringing work to new plants under construction in the US and boosting his efforts to turn around the embattled chipmaker. Intel and AWS are to coinvest in a custom semiconductor for artificial intelligence computing — what is known as a fabric chip — in a “multiyear, multibillion-dollar framework,” Intel said in a statement on Monday. The work would rely on Intel’s 18A process, an advanced chipmaking technology. Intel shares rose more than 8 percent in late trading after the
GLOBAL ECONOMY: Policymakers have a choice of a small 25 basis-point cut or a bold cut of 50 basis points, which would help the labor market, but might reignite inflation The US Federal Reserve is gearing up to announce its first interest rate cut in more than four years on Wednesday, with policymakers expected to debate how big a move to make less than two months before the US presidential election. Senior officials at the US central bank including Fed Chairman Jerome Powell have in recent weeks indicated that a rate cut is coming this month, as inflation eases toward the bank’s long-term target of two percent, and the labor market continues to cool. The Fed, which has a dual mandate from the US Congress to act independently to ensure